Pear Therapeutics, Inc.
PEARDelisted- Industry
- Services-Health Services
- SEC CIK
- 0001835567
Pear Therapeutics, Inc. was delisted in 2023; its insiders filed their last Form 4 on Apr 12, 2023; 53 institutions reported holding it in 13F filings for Q1 2023, worth $20.8M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 53
- Q1 2023, −9 vs. previous quarter
- 13F value
- $20.7M
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding PEAR, Q1 2023
No superinvestor reported holding PEAR at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Pear Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 12, 2023 (view filing)4:51 PM ET | Apr 10 | 2 days | Rocklage Scott M and 7 others10% Owner | SSaleClass A Common Stock | −16.5M | $0.12 | −$1.99M | −98.8%200.0K after | 3 lots |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | O'Brien RonanGC, CCO & Secretary | SSaleClass A Common Stock | −12.2K | $1.13 | −$13.7K | −39.5%18.6K after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | Strandberg JuliaChief Commercial Officer | SSaleClass A Common Stock | −12.7K | $1.13 | −$14.3K | −30.7%28.6K after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | Brenner Erin K.Chief Product Dev. Officer | SSaleClass A Common Stock | −8.69K | $1.13 | −$9.82K | −16.7%43.3K after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | Snow EllenChief Accounting Officer | SSaleClass A Common Stock | −8.03K | $1.13 | −$9.07K | −25.6%23.3K after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | Guiffre Christopherd TCFO, COO, Treas., & Asst. Sec. | SSaleClass A Common Stock | −19.5K | $1.13 | −$22.1K | −39.5%30.0K after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | Maricich YuriChief Medical Officer | SSaleClass A Common Stock | −12.2K | $1.13 | −$13.7K | −11.4%94.3K after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | McCann CoreyPresident and CEO | SSaleClass A Common Stock | −34.7K | $1.13 | −$39.2K | −0.4%8.21M after | |
| Jan 24, 2023 (view filing) | Jan 20 | 4 days | Jeffery KatherineChief People Officer | SSaleClass A Common Stock | −7.10K | $1.13 | −$8.02K | −46.1%8.30K after | |
| Nov 15, 2022 (view filing)8:32 PM ET | Nov 11-15 | 4 days | Rocklage Scott M and 7 others10% Owner | SSaleClass A Common Stock | −105.3K | $2.74 | −$288.3K | −16.4%534.9K after | 6 lots |
Top 10 13F holders, Q1 2023
The largest institutional positions in Pear Therapeutics, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Temasek Holdings (Private) Ltd | 26,803,573 | $6.83M | 0.04% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 16,744,113 | $4.27M | 1.09% | 00.0% | Unchanged |
| Softbank Group Corp | 12,100,078 | $3.09M | 0.04% | +12,100,078 | New |
| Arboretum Ventures, LLC | 10,859,050 | $2.77M | 8.16% | +10,859,050 | New |
| BlackRock Inc. | 3,358,886 | $856.5K | 0.00% | −98,253−2.8% | Reduced |
| Vanguard Group Inc | 2,483,472 | $633.3K | 0.00% | +712,450+40.2% | Added |
| TB Alternative Assets Ltd. | 2,071,865 | $528.3K | 0.13% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,050,879 | $268.0K | 0.00% | +1,934+0.2% | Added |
| State Street Corp | 1,007,380 | $256.9K | 0.00% | −22,498−2.2% | Reduced |
| Perceptive Advisors LLC | 900,548 | $229.6K | 0.01% | 00.0% | Unchanged |